Onderneming Viracta Therapeutics, Inc. Nasdaq
Aandelen
US92765F1084
Biotechnologie & Medisch Onderzoek
Vakgebied
Aantal werknemers: 40
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Mark Rothera
CEO | Chief Executive Officer | 61 | 19-09-22 |
Chief Tech/Sci/R&D Officer | - | - | |
Darrel Cohen
CTO | Chief Tech/Sci/R&D Officer | 59 | 07-08-23 |
Ayman El-Guindy
CTO | Chief Tech/Sci/R&D Officer | - | 06-07-21 |
Ivor Royston
BRD | Director/Board Member | 79 | 01-10-07 |
Ashleigh Barreto
IRC | Investor Relations Contact | - | 01-10-21 |
Melody Burcar
PRN | Corporate Officer/Principal | 41 | 01-09-22 |
Corporate Officer/Principal | - | 06-07-21 | |
Patric Nelson
PRN | Corporate Officer/Principal | - | 06-07-21 |
Cheryl A. Madsen
LAW | General Counsel | - | - |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Ivor Royston
BRD | Director/Board Member | 79 | 01-10-07 |
Thomas Darcy
BRD | Director/Board Member | 74 | 01-02-21 |
Barry Simon
BRD | Director/Board Member | 59 | 03-03-21 |
Mark Rothera
CEO | Chief Executive Officer | 61 | 19-09-22 |
Roger Pomerantz
CHM | Chairman | 67 | 01-06-20 |
Flavia Borellini
BRD | Director/Board Member | 65 | 14-08-21 |
Jane Barlow
BRD | Director/Board Member | 63 | 14-08-21 |
Stephen Rubino
BRD | Director/Board Member | 65 | 03-03-21 |
Sam Murphy
BRD | Director/Board Member | 47 | 01-01-19 |
Jane Chung
BRD | Director/Board Member | 53 | 10-08-22 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 39 272 434 | 38 184 370 ( 97,23 %) | 0 | 97,20 % |
Aandeel B | 0 | 10 248 | 0 | 0 |
Bedrijfsgegevens
Viracta Therapeutics, Inc.
2533 South Coast Highway 101 Suite 210
92007, Cardiff
+
http://www.viracta.com![Adres Viracta Therapeutics, Inc.](https://cdn.zonebourse.com/static/address/31271543.png)
Sector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+38,66% | 52,85 mld. | |
-7,81% | 38,87 mld. | |
+35,48% | 38,24 mld. | |
-10,77% | 26,79 mld. | |
+11,77% | 26,16 mld. | |
-17,82% | 19,9 mld. | |
+35,09% | 13,18 mld. | |
+29,17% | 12,24 mld. | |
-3,05% | 11,79 mld. |